On the implications of desexualizing vaccines against sexually transmitted diseases: reflections from a practicing pediatrician

Amanda F. Dempsey

Human papillomavirus (HPV) vaccination holds great promise for drastically reducing the incidence of HPV-associated cancers of the genital tract, and possibly also certain head and neck cancers. Unfortunately, rates of HPV vaccine utilization among adolescents are low in many countries. Many research studies have identified the fact that HPV is a sexually transmitted infection as a barrier to higher vaccination rates. This is related to providers' and parents' reluctance to discuss or consider the burgeoning sexuality of their child. An approach suggested to overcome this barrier is to "desexualize" the vaccine. This entails focusing discussions and public messages on the cancer-preventing properties of the vaccine and ignoring or minimizing information about HPV's sexual transmissibility. In an article by Velan and Yadgar, the authors argue that this approach does more harm than good. This associated commentary offers a slightly different viewpoint from one who has been "in the trenches" both clinically and from a research standpoint for many years.